Vectura strikes again as Sandoz expands VR315 deal
This article was originally published in Scrip
Vectura has signed another licensing deal for its mystery respiratory product, VR315 (thought widely to be a generic version of GlaxoSmithKline's Advair (fluticasone plus salmeterol) using Vectura's GyroHaler dry powder inhaler). The news that its European marketing partner Sandoz is to take on rest of world rights comes just days after the UK firm announced it had secured an unnamed partner for US development and commercialisation (scripintelligence.com, 03 August 2011).
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.